Glenmark Pharma Gets USFDA Approval for Seizure Drug
By Rediff Money Desk, New Delhi Jul 17, 2024 09:47
Glenmark Pharmaceuticals has received USFDA approval for its generic Topiramate capsules used to treat seizures. The drug is bioequivalent to Topamax capsules.
New Delhi, Jul 17 (PTI) Glenmark Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic Topiramate capsules used to treat certain types of seizure.
The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement.
Glenmark's Topiramate capsules USP, 15 mg and 25 mg have been determined by the FDA to be bioequivalent and therapeutically equivalent to Topamax capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the US by Glenmark Pharmaceuticals Inc., USA, it added.
Topamax Capsules, 15 mg and 25 mg market achieved annual sales of approximately USD 21.9 million, the company said citing IQVIATM sales data for the 12-month period ended May 2024.
The company said its current portfolio consists of 198 products authorised for distribution in the US marketplace and 50 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA.
The company said it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement.
Glenmark's Topiramate capsules USP, 15 mg and 25 mg have been determined by the FDA to be bioequivalent and therapeutically equivalent to Topamax capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the US by Glenmark Pharmaceuticals Inc., USA, it added.
Topamax Capsules, 15 mg and 25 mg market achieved annual sales of approximately USD 21.9 million, the company said citing IQVIATM sales data for the 12-month period ended May 2024.
The company said its current portfolio consists of 198 products authorised for distribution in the US marketplace and 50 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA.
The company said it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.80 ( -0.71)
- 44492337
- G V Films
- 0.94 (+ 9.30)
- 37404318
- Jaiprakash Power Ven
- 19.44 ( -3.38)
- 30530141
- Spicejet Ltd.
- 62.79 ( -4.25)
- 22824171
- Srestha Finvest
- 0.89 (+ 4.71)
- 21696619
MORE NEWS
World Bank Considers G20 MDB Reforms: FM
India's Finance Minister commends the World Bank's consideration of 27 out of 30...
India's Maritime Heritage: Sonowal Meets...
Union Minister Sarbananda Sonowal met with archaeologists, museologists, and historians...
India Boosts Fintech Support to Bhutan - UPI,...
India pledges further fintech support to Bhutan as UPI and RuPay cards gain popularity...